In fiscal 2025, which ended Dec 31, 2025, RxSight, Inc. reported revenue of $134.5 million, down 3.9% from the year before. It recorded a net loss of $38.9 million. The operating loss came to $48.2 million, an operating margin of -35.8%. Diluted earnings per share were -$0.95. Over the twelve months ended Sep 30, 2026, revenue was $115.3 million and the net loss was $53.4 million. Across the 5 fiscal years shown, revenue grew from $22.6 million in fiscal 2021 to $134.5 million in fiscal 2025, about 56.2% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
|---|---|---|---|---|---|---|
| Revenue |
115
-18.9%
|
134
-3.9%
|
140
+57.1%
|
89
+81.8%
|
49
+116.9%
|
23
|
| Cost of revenue |
29
-18.2%
|
31
-23.2%
|
41
+16.1%
|
35
+27.6%
|
28
+53.1%
|
18
|
| Gross profit |
86
-19.1%
|
103
+4.1%
|
99
+84.0%
|
54
+152.1%
|
21
+372.2%
|
5
|
| Research and development |
37
-5.2%
|
39
+12.2%
|
34
+18.3%
|
29
+11.8%
|
26
+6.0%
|
24
|
| Selling, general and administrative |
117
+3.7%
|
113
+11.1%
|
101
+35.6%
|
75
+27.5%
|
59
+78.8%
|
33
|
| Operating expenses |
—
|
151
+11.3%
|
136
+30.8%
|
104
+22.7%
|
85
+47.7%
|
57
|
| Operating income |
-61
-35.1%
|
-48
-30.7%
|
-37
+26.4%
|
-50
+20.9%
|
-63
-19.9%
|
-53
|
| Pretax income |
-53
-49.3%
|
-39
-41.9%
|
-27
+43.6%
|
-49
+27.2%
|
-67
-37.1%
|
-49
|
| Income tax |
0
+74.0%
|
0
+32.0%
|
0
+150.0%
|
0
+122.2%
|
0
+12.5%
|
0
|
| Net income |
-53
-49.3%
|
-39
-41.8%
|
-27
+43.5%
|
-49
+27.2%
|
-67
-37.1%
|
-49
|
| Basic EPS |
-1.29
-46.5%
|
-0.95
-33.8%
|
-0.71
+49.6%
|
-1.41
+41.5%
|
-2.41
+32.5%
|
-3.57
|
| Diluted EPS |
-1.29
-46.5%
|
-0.95
-33.8%
|
-0.71
+49.6%
|
-1.41
+41.5%
|
-2.41
+32.5%
|
-3.57
|
| Weighted average shares, basic |
41
+1.9%
|
41
+5.1%
|
39
+12.8%
|
34
+24.6%
|
28
+103.0%
|
14
|
| Weighted average shares, diluted |
41
+1.9%
|
41
+5.1%
|
39
+12.8%
|
34
+24.6%
|
28
+103.0%
|
14
|
| Other measures | ||||||
| Depreciation and amortization |
4
+23.3%
|
3
-8.6%
|
4
-12.3%
|
4
+5.0%
|
4
-2.3%
|
4
|
| EBITDA |
-58
-35.9%
|
-45
-35.0%
|
-33
+27.7%
|
-46
+22.6%
|
-59
-21.8%
|
-49
|
| Interest coverage |
-4,389.64x
|
-2,536.37x
|
-1,755.14x
|
-15.14x
|
-12.80x
|
-14.34x
|
| Margins | ||||||
| Gross margin |
74.77%
|
76.60%
|
70.71%
|
60.36%
|
43.52%
|
19.99%
|
| Operating margin |
-53.31%
|
-35.84%
|
-26.34%
|
-56.23%
|
-129.21%
|
-233.64%
|
| Pretax margin |
-46.17%
|
-28.91%
|
-19.59%
|
-54.55%
|
-136.20%
|
-215.46%
|
| Profit margin |
-46.28%
|
-28.96%
|
-19.62%
|
-54.57%
|
-136.22%
|
-215.50%
|
| EBITDA margin |
-50.17%
|
-33.41%
|
-23.79%
|
-51.65%
|
-121.28%
|
-216.05%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Ophthalmic Goods (SIC 3851)
- Listed as
- RXST (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Aliso Viejo, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1111485
- Former names
- CALHOUN VISION INC (until Mar 20, 2014)
Other Ophthalmic Goods companies
- Alcon Inc ALC
- Cooper Companies, Inc. COO
- Bausch & Lomb Corp BLCO
- Warby Parker Inc. WRBY
- National Vision Holdings, Inc. EYE
- Staar Surgical Co STAA
- Innovative Eyewear Inc LUCY
Source: SEC EDGAR filings. This is company-reported data, not investment advice.